At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating ...

Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...

In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and Exposition which assessed a triplet nonchemotherapy regimen in older and medically unfit patients with ...

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL.

In this video, Brian T. Hill, MD, PhD, discusses data from the Smart Stop trial assessing the effects of a novel targeted combination therapy in patients with newly diagnosed diffuse large B-cell ...

Doctors may not need to avoid steroids before biopsy in patients with a common aggressive lymphoma, according to a new study.

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

This was a study led by Dr. Pallawi Torka from Memorial Sloan Kettering that we participated in, where they performed as a ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...